Fewer investment dollars are going to oncology-focused and platform technology companies, but there has been an uptick in investment in disease areas – even at the preclinical stage – that just a few years ago would have had difficulty attracting it.
The growing trend was highlighted during a panel that kicked off the BIO CEO and Investor Conference on 26-27 February. Before the panel, managing director of HSBC Innovation Jonathan Norris presented a report on biopharma investment showing that in 2023 there were 21 venture capital investment deals worth $1.1bn in the field of autoimmune disorders as well as 87 deals worth $2.6bn in the field of neurology. That still paled in comparison to the 162 deals totaling $5
Key Takeaways
-
At BIO CEO, a panelist remarked that immunology is “much hotter than it ever was,” along with neurology and metabolic disorders.
-
HSBC’s Jonathan Norris told Scrip that investment in platform technologies and oncology has fallen because, while interest remains strong, investors have shifted focus to clinical-stage assets
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?